| Brainstorm | New from Nature Vaccines: Yangzhuo Gu et al.: Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases → https://www.nature.com/articles/s41392-023-01479-4 | 01:39 |
|---|---|---|
| Brainstorm | New from StatNews: Biotech: STAT+: Argenx antibody drug significantly slows progression of nerve disorder that robs patients of muscle strength → https://www.statnews.com/2023/07/17/vyvgart-cipd-argenx-chronic-inflammatory-demylinating-polyneuropathy/ | 07:10 |
| Brainstorm | New from Science-Based Medicine: RFK Jr.: A fart-filled argument gives way to an antisemitic conspiracy theory that COVID-19 is an “ethnically targeted” bioweapon: Late last week, RFK Jr. endured some [... want %more?] → https://sciencebasedmedicine.org/rfk-jr-a-fart-filled-argument-gives-way-to-an-antisemitic-conspiracy-theory-that-covid-19-is-an-ethnically-targeted-bioweapon/ | 09:13 |
| Brainstorm | New from EMA: What's new: Medicine: Human medicines European public assessment report (EPAR): Kineret, anakinra, Arthritis, Rheumatoid;COVID-19 virus infection, Date of authorisation: 08/03/2002, Revision: 34, Status: Authorised → https://www.ema.europa.eu/en/medicines/human/EPAR/kineret | 11:11 |
| Brainstorm | New from EMA: What's new: Medicine: Human medicines European public assessment report (EPAR): Nimenrix, meningococcal groups A, C, W-135 and Y conjugate vaccine, Meningitis, Meningococcal, Date of authorisation: 20/04/2012, Revision: 36, Status: Authorised → https://www.ema.europa.eu/en/medicines/human/EPAR/nimenrix | 11:39 |
| Brainstorm | New from PubMed: Humoral immune responses to inactivated COVID-19 vaccine up to 1 year in children with chronic hepatitis B infection: CONCLUSION: Inactivated vaccination could elicit more robust and durable antibody responses to the wild-type SARS-CoV-2 strain in CHB children than in CHB adults but showed inferior responses to [... want %more?] → https://pubmed.ncbi.nlm.nih.gov/37457966/ | 12:45 |
| Brainstorm | New from StatNews: Pharma: STAT+: Pharmalittle: Alzheimer’s diagnosis revamp embraces rating scale similar to cancer; FTC seeks info on Pfizer-Seagen deal → https://www.statnews.com/pharmalot/2023/07/17/alzheimers-ftc-pfizer-seagen-alnylam-bridgebio-gsk-catalent-argenx-jnj-covid19-tuberculosis/ | 15:30 |
| Brainstorm | New from BBC Health: Drug donanemab seen as turning point in dementia fight: The antibody treatment donanemab helps clear the brain of a damaging protein that builds up in Alzheimer's. → https://www.bbc.co.uk/news/health-66221116 | 16:29 |
| Brainstorm | New from StatNews: STAT+: Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure: The CRISPR enzyme CasX comes with key potential advantages, including that it’s free from the intellectual property fight surrounding Cas9, the original DNA-cutting tool. → https://www.statnews.com/2023/07/17/sickle-cell-sanofi-scribe-license-crispr-enzyme/ | 16:48 |
| Brainstorm | New from StatNews: Health Tech: Nearly 8,000 blood tests recalled over risk of missed heart attack diagnosis → https://www.statnews.com/2023/07/17/quidel-blood-test-heart-attack-recall/ | 18:52 |
| Brainstorm | New from StatNews: FDA approves RSV monoclonal antibody for infants, young children at high risk: The FDA approved a monoclonal antibody to protect infants and young children from severe illness caused by RSV on Monday, a potential game-changer for the disease. → https://www.statnews.com/2023/07/17/fda-approves-rsv-monoclonal-antibody-for-infants-young-children-at-high-risk/ | 19:02 |
| Brainstorm | New from Contagion Live: FDA Approves Nirsevimab for RSV in Infants: The monoclonal antibody is indicated for the prevention of respiratory syncytial virus (RSV) in newborns, infants, and young children. → https://www.contagionlive.com/view/fda-approves-nirsevimab-for-rsv-in-infants | 19:49 |
| Brainstorm | New from Ars Technica: Eli Lilly drug shown to slow Alzheimer’s progression: Dementia experts hail "watershed moment" after trial results for donanemab antibody treatment. → https://arstechnica.com/?p=1954453 | 20:55 |
| Brainstorm | New from Contagion Live: Identifying COVID-19 Risk Factors: Insights From 4 Vaccine Trials: Workplace exposure and living conditions were associated with higher COVID-19 risk, while previous infection, age 65 or older, and Black/African American race were correlated with [... want %more?] → https://www.contagionlive.com/view/identifying-covid-19-risk-factors-insights-from-4-vaccine-trials | 23:07 |
Generated by irclog2html.py 2.17.0 by Marius Gedminas - find it at https://mg.pov.lt/irclog2html/!